Phone: 86-13022869828
Mail: sales28@interlgroup.com
Add: Room 305 , 3/F , Haipai Decoration Office Building , Yudu Avenue , Yuncheng , Shanxi
Obeticholic Acid powder Raw Materials CAS 459789-99-2
Product Overview:
Obeticholic Acid powder, also known as 6-ethyl channedeoxycholic acid, is a novel derivative of channedeoxycholic acid (CDCA) in human primary bile acids. Obeticholic acid powder is a natural ligand of farnesate derivative X receptor (FXR). Obeticholic Acid is a farnesol X receptor agonist. Obeticholic acid indirectly inhibits cytochrome 7A1 (CYP7A1) gene expression by activating farnesol X receptor. Since CYP7A1 is a rate-limiting enzyme for cholic Acid biosynthesis, Obeticholic Acid can inhibit cholic acid synthesis for the treatment of primary biliary cirrhosis and non-alcoholic fatty liver disease.
Obeticholic Acid powder Raw Materials CAS 459789-99-2 Attributes
MF:C26H44O4
MW:420.63
EINECS:810-245-2
Specification:99% min Obeticholic Acid powder
Sample:Obeticholic Acid powder
Keywords:Obeticholic Acid
Appearance:white powder
Storage: Cool Dry Place
Brand: Global ASAP Nutrition Factory
Shelf Life: 2 Years
Test Method: HPLC
Obeticholic Acid powder Raw Materials CAS 459789-99-2 Details
Bile acid synthesis and transport: OCA inhibits the synthesis of bile acids in the liver and promotes the excretion of bile acids from the liver into the bile duct, thereby reducing the accumulation of bile acids in the liver.
Hepatic inflammation and fibrosis: OCA can reduce liver inflammation and fibrosis, two pathological processes that are key features of many chronic liver diseases.
Glucose and lipid metabolism: FXR also plays a role in glucose and lipid metabolism, and the activation of OCA may have an impact on these metabolic processes.
Applications of Obeticholic Acid powder
Primary Biliary Cholangitis (PBC): PBC is a chronic autoimmune liver disease characterized by progressive destruction of the small bile ducts within the liver. OCA may be used in patients with PBC who have an inadequate response to or are unable to tolerate ursodeoxycholic acid (UDCA).Nonalcoholic Steatohepatitis (NASH): NASH is a liver disease associated with abnormal accumulation of fat in the liver, which can lead to liver inflammation and fibrosis. OCA is being studied for the treatment of NASH-related liver fibrosis.
